Anti-spasticity medications.
Spasticity is common in patients with a variety of central nervous system disorders. It can lead to significant disability or cause complications that may result in severe morbidity. In such patients, treatment of spasticity is warranted. Several oral and parenteral medications are available for use in the treatment of spasticity. This article reviews the pharmacological properties and therapeutic effectiveness of these medications to provide a practical objective guide for physicians who may be involved in the management of spasticity.
Al-Shahrani
Abdulrahman M
AM
Department of Neurology, King Fahd Hospital of the University, PO Box 40180, Al-Khobar, Kingdom of Saudi Arabia. amalshahrani@hotmail.com
D001418:Baclofen / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D003000:Clonidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D009125:Muscle Relaxants, Central / Q000627:therapeutic use; D009128:Muscle Spasticity / Q000188:drug therapy*; D010276:Parasympatholytics / Q000627:therapeutic use*
D009125:Muscle Relaxants, Central; D010276:Parasympatholytics; D001569:Benzodiazepines; C023754:tizanidine; D019274:Botulinum Toxins, Type A; D001418:Baclofen; D003000:Clonidine